医学
咪唑啉
美罗华
耐火材料(行星科学)
生活质量(医疗保健)
肾病综合征
中止
钙调神经磷酸酶
儿科
内科学
移植
天体生物学
物理
护理部
淋巴瘤
作者
Toshiyuki Takahashi,Takayuki Okamoto,Isao Yokota,Yasuyuki Sato,Asako Hayashi,Yasuhiro Ueda,Hayato Aoyagi,Michihiko Ueno,Norio Kobayashi,Kimiaki Uetake,Masayoshi Nakanishi,Tadashi Ariga
摘要
Rituximab (RTX) is an effective treatment for maintaining remission in patients with nephrotic syndrome (NS), but there are few reports on the effect of RTX treatment on quality of life (QOL). The purpose of this study was to examine the effect of periodically repeated RTX treatment from the perspective of QOL.We systematically assessed the QOL of pediatric patients with refractory NS and parents' perceptions of their children's QOL through a 2 year RTX treatment protocol. Pediatric patients from Hokkaido University Hospital with refractory NS who met our specific criteria were enrolled between January 2015 and December 2015. The RTX infusion was performed 4 times at 6-month intervals, followed by mizoribine administration with early discontinuation of calcineurin inhibitors. Quality of life scores were measured by the Pediatric Quality of Life Inventory version 4.0 (PedsQL) at each RTX administration and evaluated 2 years later.Twenty-two patients were analyzed. The patients' QOL and their parents' perceptions of their QOL improved over our 2 year treatment protocol. Nevertheless, the parents' scores were lower than the patients' scores on all scales, with slower improvement.Our treatment protocol showed a significant improvement of QOL in patients with refractory NS. Although the risk of the RTX treatment should be considered, the treatment is useful for patients with refractory NS.
科研通智能强力驱动
Strongly Powered by AbleSci AI